Showing 1 posts of 1 posts found.
Oxford-based biotech firm Adaptimmune has secured some significant financial support whilst also making changes to its board. David Mott (pictured), …
How chronic disease creates opportunity on diagnostic and therapeutic pipelines
EnteroBiotix appoints former GSK Chief Medical Officer to board
Stryker invests US$400m in CMR Surgical and secures option to acquire business
AI: an early warning system for patient safety
Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial